Katarina Miljević/LinkedIn
Jul 15, 2026, 13:43
Katarina Miljević: New Insights into Recombinant tPA and FXI Inhibition at ISTH 2026
Katarina Miljević, Postdoctoral Research Scientist at the Department of Clinical Pharmacology, Medical University of Vienna, shared a post on LinkedIn:
“I was delighted to present two posters at the ISTH 2026 Congress in Paris, highlighting research from the Department of Clinical Pharmacology MedUni Vienna, focusing on:
- Pharmacokinetic and pharmacodynamic equivalence of recombinant tPA products
- FXI inhibition with cenvacibart and its effects on hemodialysis circuit clotting
Grateful to all collaborators and co-authors who contributed to these projects.
Looking forward to the discussions and future research opportunities.”
Stay updated with Hemostasis Today.
-
Aug 31, 2026, 04:28Reza Hafidz Irawan։ Automated Antibody Titration With Erytra Eflexis
-
Aug 31, 2026, 04:17Safa Chenganath: Stenosis vs Thrombosis – Hemodialysis Vascular Access
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session
-
Aug 30, 2026, 17:02David McGlasson: A 2020 Article Reaches 8,000 Reads
-
Aug 30, 2026, 16:18Tushar Namdeo: Platelets in Different Diseases